A drug called gefitinib tablets IP 250 mg is used to treat non-small cell lung cancer (NSCLC), which is brought on by particular genetic mutations in the EGFR gene. The tyrosine kinase inhibitor (TKI) medicine family includes gefitinib, the active pharmaceutical ingredient (API) in these tablets. It functions by preventing EGFR from becoming active, which prevents the growth and spread of lung cancer cells.
Patients with EGFR mutations and advanced or metastatic NSCLC are typically prescribed 250 mg gefitinib tablets. Skin rash, diarrhoea, nausea, and altered liver function are examples of typical adverse effects. To reduce potential adverse effects and guarantee therapy effectiveness in patients with NSCLC, regular medical monitoring is crucial throughout the course of the treatment.